The market for luteinizing hormone releasing hormone agonists is anticipated to record a significant CAGR during the forecast period, i.e., 2021-2029. The LHRH-agonist therapy is widely used for patients with prostate cancer. In males, LHRH agonist manages the growth of prostate cancer by stopping normal hormonal functions in the body. Initially, LHRH agonist stimulates the production of testosterone for a couple of weeks and when the LHRH agonist reaches an elevated level, the human body stops the production of new LHRH. Owing to the consequence, there is no more production of testosterone in the body and low levels of testosterone drops the level of prostate cancer cells in the body. The market is thriving primarily on account of the growing cases of prostate cancer in males.
The global luteinizing hormone releasing hormone agonists market is segmented by drug type into Eligard, Zoladex, Lupron, Vantas and others. Amongst these segments, the Eligard segment is projected to grab a significant market share in the year 2021. The growth of the segment can be attributed to the rising usage of the drug for the treatment of prostate cancer.
Regionally, the global luteinizing hormone releasing hormone agonists market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
The market for LHRH agonists in North America is anticipated to dominate the market by the end of 2029 owing to the rising incidence rate of prostate cancer in the region along with the increasing investments for the development of targeted drug therapies to treat prostate cancer. Alternatively, the market in the Asia Pacific region is estimated to be the fastest growing by recording a significant CAGR during the forecast period on the back of growing awareness for the treatment of prostate cancer coupled with the improvements in healthcare infrastructure. Further, collaborations of key players with various government institutions for the treatment of prostate cancer along with the presence of online portals providing detailed information regarding luteinizing hormone releasing hormone agonists is also anticipated to foster the market growth over the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
The global luteinizing hormone releasing hormone agonists market is further classified on the basis of regions as follows:
Our in-depth analysis of the global luteinizing hormone releasing hormone agonists market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The high effectiveness of LHRH agonists in prostate cancer is one of the major factors driving the market growth.
The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2021-2029.
The concern for the side effects associated with the hormone is one of the major factors estimated to act as barriers to the growth of the market.
The major companies in the market are F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals Corporation, Siemens Healthcare Private Limited, Pfizer Inc., Clovis Oncology, Genomic Health, Inc., Myriad Genetics, Inc., and others.
The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market in North America is anticipated to hold the dominating share by the end of 2029 on account of the growing advancements in the development of novel drugs.
The luteinizing hormone releasing hormone agonists market is segmented by drug type, patient type, end users, and by region.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization